Company intelligence / Profile preview

LSP Bio

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

LSP Bio is a South Korean biotechnology company focused on developing innovative treatments for metabolic diseases, including obesity and type 2 diabetes. The company utilizes its proprietary platform technology to develop long-acting peptide and small molecule therapeutics, specifically targeting the GLP-1, GIP, and Glucagon receptors. Their lead programs aim to provide improved efficacy and patient convenience compared to existing injectable treatments. LSP Bio is currently advancing its pipeline through pre-clinical stages with the goal of entering clinical trials for metabolic and inflammatory indications.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculePeptides
Industry: Biotech

Drug pipeline

1 asset

RenehaVis

Unknown

Beyond the preview

Go deeper on LSP Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSP Bio.

Explore the full profile